{"schema_version":"1.0","type":"article","title":"⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣","url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html","markdown_url":"https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.md","lang":"zh-Hant","date":"2026-05-31","publish_at":"2026-05-31T10:30:00+08:00","updated_at":"2026-05-31","category":"商業分析系列","topic":"臨床與 CMC","tags":["Tavneos","Amgen","罕病藥","FDA","資料完整性","肝毒性","撤市風險"],"summary":"Tavneos 從罕病明星藥站上撤市邊緣，真正危機不只是日本死亡通報與肝毒性，而是 FDA 對 ADVOCATE 試驗資料完整性的嚴重指控。","key_points":[],"facts":[],"sections":["01｜日本 20 例死亡通報，讓 Tavneos 的肝毒性問題被推到台前","02｜真正致命的，不只是肝毒性，而是 FDA 對資料完整性的指控","03｜Tavneos 當年本來就是一個充滿爭議的核准","04｜Amgen 為什麼不能輕易放棄？","05｜標籤更新救得了 Tavneos 嗎？","06｜罕見病藥物的兩難：患者需求不能變成資料鬆綁的藉口","結語｜Tavneos 的真正教訓：罕見病可以有彈性，但資料不能有灰色地帶"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"CDER proposes to withdraw approval of TAVNEOS","source":"FDA","date":"","url":""},{"title":"CDER proposes to withdraw approval of TAVNEOS","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"\"CDER proposes to withdraw approval of TAVNEOS","source":"FDA\"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/amgens-rare-disease-drug-linked-deaths-liver-injuries-japan-wsj-reports-2026-05-15/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/amgens-rare-disease-drug-linked-deaths-liver-injuries-japan-wsj-reports-2026-05-15/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-liver-injury-cases-tied-amgens-rare-disease-drug-2026-03-31/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-warns-liver-injury-cases-tied-amgens-rare-disease-drug-2026-03-31/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"An Important Update Regarding TAVNEOS® (avacopan","source":"Amgen","date":"","url":""},{"title":"An Important Update Regarding TAVNEOS® (avacopan","source":"","date":"","url":""},{"title":"www.amgen.com","source":"","date":"","url":""},{"title":"\"An Important Update Regarding TAVNEOS® (avacopan","source":"Amgen\"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"https://www.fda.gov/media/192160/download?attachment=","source":"","date":"","url":"https://www.fda.gov/media/192160/download?attachment="},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"\"Letter NOOH Taveneos (avacopan)\"","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：Tavneos 危機與撤市風險總覽","url":"https://drugnews.com.tw/assets/articles/tavneos-safety-data-integrity-crisis/dcard-01.webp"},{"alt":"Dcard 原圖：Tavneos 資料完整性與 FDA 指控","url":"https://drugnews.com.tw/assets/articles/tavneos-safety-data-integrity-crisis/dcard-02.png"},{"alt":"Dcard 原圖：Tavneos 罕病藥監管教訓","url":"https://drugnews.com.tw/assets/articles/tavneos-safety-data-integrity-crisis/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/tavneos-safety-data-integrity-crisis/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-05-31）。⚠️ Tavneos 危機：20 例死亡通報、資料完整性疑雲，Amgen 罕病明星藥站上撤市邊緣。https://drugnews.com.tw/articles/2026-05-31-tavneos-safety-data-integrity-crisis.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-05-31-tavneos-safety-data-integrity-crisis-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}